F
Fluent BioSciences Inc.
Solutions for single cell biology
About Fluent BioSciences Inc.
Fluent BioSciences, founded in 2018, specializes in single-cell RNA sequencing (scRNA-seq) technologies designed to advance scientific research. The company operates in the life sciences market, providing RNA sequencing kits and platforms that enable researchers to analyze individual cells with high precision. Fluent BioSciences serves academic institutions, biotechnology firms, and pharmaceutical companies, offering products like the PIPseq platform and SEA Kit for custom applications. The business model revolves around selling these specialized kits and platforms, generating revenue through direct sales and long-term partnerships. The company's technology allows for rapid processing of fresh samples, ensuring high-quality data without sample degradation. Fluent BioSciences is backed by leading early-stage life science investors and guided by a team of industry veterans with extensive experience in commercializing life science technologies.
Source: Dealroom company dataAt a glance
- Founded
- 2018
- Headquarters
- Watertown, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Institute of General Medical Sciences
Small Business Innovation Research
Series A5 investors entered at this stage
Illumina Ventures
Samsara BioCapital
Civilization Ventures
Cowin Venture- VCVC23
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fluent BioSciences Inc. on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fluent BioSciences Inc. on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.